4-(sec-Butyl)-1,2-dicyanobenzene

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-(sec-Butyl)-1,2-dicyanobenzene
• 英文别名: 4-Butan-2-ylbenzene-1,2-dicarbonitrile
• 化学式: C₁₂H₁₂N₂
• 分子量: 184.241
• InChiKey: OQBMVFUBQDCWJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  47.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴丁烷 、 1,2-二氰基苯 在 氨 、 氢化钾 作用下， 反应 0.91h， 以19%的产率得到2-(sec-Butyl)benzonitrile
  参考文献：
  名称：

  Panteleeva; Bilkis; Steingarts, Russian Journal of Organic Chemistry, 1998, vol. 34, # 11, p. 1632 - 1639

  摘要：

  DOI：

文献信息

• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
  申请人：Incyte Corporation

  公开号：US11331320B2

  公开（公告）日：2022-05-17

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂芳基取代的吡咯并[2,3-b]吡啶和杂芳基取代的吡咯并[2,3-b]嘧啶，它们可以调节 Janus 激酶的活性，并可用于治疗与 Janus 激酶活性有关的疾病，例如包括免疫相关疾病、皮肤疾病、骨髓增生性疾病、癌症和其他疾病。
• [EN] ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE COMPRISING SAME<br/>[FR] COMPOSÉ ORGANIQUE, ET ÉLÉMENT ÉLECTRONIQUE ET DISPOSITIF ÉLECTRONIQUE LE COMPRENANT<br/>[ZH] 有机化合物及包含其的电子元件和电子装置
  申请人：[en]SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD.;[zh]陕西莱特光电材料股份有限公司

  公开号：WO2022262365A1

  公开（公告）日：2022-12-22

  本申请涉及一种有机化合物及包含其的电子元件和电子装置。本申请的有机化合物结构式如式1表示，将该有机化合物应用于有机电致发光器件中，可显著改善器件的性能。
• OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME
  申请人：DONG-A ST CO., LTD.

  公开号：US20170050955A1

  公开（公告）日：2017-02-23

  Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.
• HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Incyte Corporation

  公开号：US20200338077A1

  公开（公告）日：2020-10-29

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
• US9809583B2
  申请人：——

  公开号：US9809583B2

  公开（公告）日：2017-11-07